PDTX模型的研究进展

细胞源性异种移植(cell line-derived xenografts,CDX)与原发肿瘤相比失去了肿瘤的异质性和基因的多样性,在临床前的实验中不能有效评估肿瘤药物的疗效和安全性,致使临床药物高消耗而没有达到治疗疾病的目的,严重阻碍了临床药物的发展;人源性肿瘤组织异种移植(patient-derived tumor xenografts,PDTX)保持了原发肿瘤的分子学、基因学和病理学特征,而且经过在小鼠体内传代它仍保持了原发肿瘤的这些特性,为肿瘤的个体化治疗提供了更好的模型。PDTX模型的这些特性与CDX模型相比在肿瘤的个体化治疗方面更具有指导意义。本文将就PDTX模型的特征及其在肿瘤研究领域中的应用作系统阐述。

Research Progress of PDTX Model

Effective preclinical evaluation of the efficacy and safety of antitumor drugs is largely limited by the experimental use of cell line-derived tumor xenografts (CDX) which are deficient in the characteristics of tumor heterogeneity and genetic diversity as compared to primary tumors. As such, the overuse of drugs often fails to treat diseases and the development of clinical drugs is significantly impeded. Patient-derived tumor xenografts (PDTX) inherit intact molecular, genetic and pathologic features from primary tumors, which are sustainable through serial passaging in mice, and thus provide a better alternative model than CDX for developing personalized antitumor therapy. In this review, the characteristics of PDTX model and its applications in cancer research will be summarized.